NASDAQ:ATOS - Atossa Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.85
▼ -0.03 (-3.41%)

This chart shows the closing price for ATOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atossa Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATOS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Atossa Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $0.85.

This chart shows the closing price for ATOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Atossa Therapeutics. This rating has held steady since August 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/18/2020Maxim GroupReiterated RatingBuy$8.00Medium
9/17/2020Ascendiant Capital MarketsInitiated CoverageBuy$7.00High
7/31/2020Maxim GroupReiterated RatingBuy$8.00Low
7/17/2020Maxim GroupBoost Price Target$4.00 ➝ $8.00High
7/16/2020Maxim GroupReiterated RatingPositiveHigh
5/23/2020Maxim GroupInitiated CoverageBuy$4.00Low
4/28/2020Maxim GroupInitiated CoverageBuy$4.00Low
4/17/2020Maxim GroupReiterated RatingBuy$4.00Low
12/18/2019Maxim GroupUpgradeHold ➝ BuyHigh
6/27/2019Maxim GroupDowngradeBuy ➝ HoldLow
3/26/2019Maxim GroupReiterated RatingBuy$9.00High
1/9/2019Maxim GroupReiterated RatingBuy$5.00High
12/3/2018Maxim GroupSet Price TargetBuy$5.00High
11/14/2018Maxim GroupReiterated RatingBuy$5.00Medium
10/11/2018Maxim GroupReiterated RatingBuy$7.00Low
7/18/2018Maxim GroupReiterated Rating$2.47$10.00Low
6/26/2018Maxim GroupReiterated RatingBuy$10.00Low
5/15/2018Noble FinancialSet Price TargetBuy$10.00High
5/14/2018Maxim GroupSet Price TargetBuy$10.00Medium
5/3/2018Maxim GroupSet Price TargetBuy$10.00Low
1/26/2018Maxim GroupInitiated CoverageBuy ➝ Buy$24.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Atossa Therapeutics logo
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $0.85
Low: $0.84
High: $0.90

50 Day Range

MA: $1.13
Low: $0.85
High: $1.57

52 Week Range

Now: $0.85
Low: $0.84
High: $9.80

Volume

1,642,787 shs

Average Volume

1,966,820 shs

Market Capitalization

$107.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Atossa Therapeutics?

The following Wall Street research analysts have issued stock ratings on Atossa Therapeutics in the last year: StockNews.com.
View the latest analyst ratings for ATOS.

What is the current price target for Atossa Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Atossa Therapeutics in the last year.
View the latest price targets for ATOS.

What is the current consensus analyst rating for Atossa Therapeutics?

Atossa Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ATOS.

How do I contact Atossa Therapeutics' investor relations team?

Atossa Therapeutics' physical mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company's listed phone number is (206) 588-0256 and its investor relations email address is [email protected] The official website for Atossa Therapeutics is www.atossagenetics.com. Learn More about contacing Atossa Therapeutics investor relations.